Scott Morenstein
Director/Board Member at Primmune Therapeutics, Inc.
Profile
Scott D.
Morenstein is the founder of Seaview Securities LLC, which was founded in 2010.
He held the title of Member at Seaview Securities LLC.
Mr. Morenstein's current jobs include being a Director at Palvella Therapeutics, Inc., Primmune Therapeutics, Inc., Antios Therapeutics, Inc., Molecular Templates OpCo, Inc., and Avenge Bio, Inc. Mr. Morenstein's former jobs include being a Director at Synta Pharmaceuticals Corp.
from 2015 to 2016, an Independent Director at Celator Pharmaceuticals, Inc. from 2013 to 2016, a Director at Gemin X Pharmaceuticals US, Inc., a Managing Director at Caxton Advantage Venture Partners, a Managing Director at Caxton Alternative Management LP from 2013 to 2022, a Managing Director at Valence Life Sciences LLC from 2012 to 2013, a Director at Velicept Therapeutics, Inc., an Independent Director at Molecular Templates, Inc. from 2017 to 2023, and a Principal at Lehman Brothers, Inc. from 2000 to 2002.
Mr. Morenstein's education includes an undergraduate degree from the University of Pennsylvania in 1998 and an MBA from Harvard Business School.
Scott Morenstein active positions
| Companies | Position | Start |
|---|---|---|
Primmune Therapeutics, Inc.
 Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | Director/Board Member | - |
Molecular Templates OpCo, Inc.
 Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | Director/Board Member | - |
Antios Therapeutics, Inc.
 Antios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA. | Director/Board Member | - |
Palvella Therapeutics, Inc.
 Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Director/Board Member | - |
Avenge Bio, Inc.
 Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Director/Board Member | - |
Former positions of Scott Morenstein
| Companies | Position | End |
|---|---|---|
| MOLECULAR TEMPLATES, INC. | Director/Board Member | 2023-02-28 |
Caxton Alternative Management LP
 Caxton Alternative Management LP Investment ManagersFinance Caxton Alternative Management LP (do-business-as CAM Capital) is a single-family office which was founded in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. Headquartered in New York City, CAM Capital manages assets exclusively for entities related to Mr. Kovner and its senior employees. | Chief Executive Officer | 2022-01-31 |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Director/Board Member | 2016-07-21 |
| CELATOR PHARMACEUTICALS INC | Director/Board Member | 2016-07-11 |
| ░░░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Training of Scott Morenstein
| University of Pennsylvania | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MOLECULAR TEMPLATES, INC. | Health Technology |
| Private companies | 14 |
|---|---|
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
Seaview Securities LLC
 Seaview Securities LLC Investment Banks/BrokersFinance Seaview Securities LLC provides investment banking services focused on the life sciences industry. The firm's services include private placements, mergers & acquisitions, financial and business strategy advisory, and underwriting services. The company was founded in January 2002 by Russell L. Pollack and Joseph P. Dougherty and is headquartered in New York, NY. | Finance |
Celator Pharmaceuticals, Inc.
 Celator Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Celator Pharmaceuticals, Inc. engages in the research and development of biopharmaceutical products. The company was founded by Lawrence David Mayer, and Marcel B. Bally in 1999 and is headquartered in Ewing, NJ. | Health Technology |
Gemin X Pharmaceuticals US, Inc.
 Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Health Technology |
Caxton Advantage Venture Partners
 Caxton Advantage Venture Partners Investment ManagersFinance Founded in 2004 by Eric Roberts and Rachel Leheny, Caxton Advantage Venture Partners is a venture capital firm located in New York City. | Finance |
| Lehman Brothers, Inc. /Istanbul Division/ | Finance |
Caxton Alternative Management LP
Caxton Alternative Management LP Investment ManagersFinance Caxton Alternative Management LP (do-business-as CAM Capital) is a single-family office which was founded in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. Headquartered in New York City, CAM Capital manages assets exclusively for entities related to Mr. Kovner and its senior employees. | Finance |
Valence Life Sciences LLC
 Valence Life Sciences LLC Investment ManagersFinance Valence Life Sciences LLC (Valence Life Sciences) is an venture capital firm founded in 2012 by Rachel Anne Leheny and Eric Wayne Roberts. The firm is headquartered in New York. | Finance |
Velicept Therapeutics, Inc.
 Velicept Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Velicept Therapeutics, Inc. manufactures biopharmaceutical products. The firm offers Solabegron, which is used for the treatment of overactive bladder in women and irritable bowel syndrome. The company was founded in 2015 and is headquartered in Wayne, PA. | Health Technology |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Health Technology |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA. | Commercial Services |
Antios Therapeutics, Inc.
Antios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA. | Health Technology |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | Finance |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Scott Morenstein
